GlobeNewswire: Sunesis Pharmaceuticals, Inc. Contains the last 10 of 266 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:35:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/11/30/2136415/0/en/Sunesis-Pharmaceuticals-and-Viracta-Therapeutics-Announce-Definitive-Merger-Agreement.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement2020-11-30T12:30:00Z<![CDATA[Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies]]>https://www.globenewswire.com/news-release/2020/11/16/2127765/0/en/Sunesis-Pharmaceuticals-Reports-Third-Quarter-2020-Financial-Results-and-Recent-Highlights.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights2020-11-16T21:05:00Z<![CDATA[Sunesis to Host Conference Call Today at 4:30 PM Eastern Time Sunesis to Host Conference Call Today at 4:30 PM Eastern Time]]>https://www.globenewswire.com/news-release/2020/11/09/2122596/0/en/Sunesis-Pharmaceuticals-to-Host-Conference-Call-on-November-16th-to-Discuss-Third-Quarter-2020-Financial-Results-and-Recent-Highlights.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights2020-11-09T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2020.]]>https://www.globenewswire.com/news-release/2020/10/12/2106757/0/en/Sunesis-Pharmaceuticals-Announces-Presentation-of-SNS-510-Preclinical-Data-at-the-32nd-EORTC-NCI-AACR-Symposium-on-Molecular-Targets-and-Cancer-Therapeutics.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics2020-10-12T11:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.]]>https://www.globenewswire.com/news-release/2020/09/03/2088331/0/en/Sunesis-Pharmaceuticals-Announces-Participation-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences2020-09-03T11:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.]]>https://www.globenewswire.com/news-release/2020/09/02/2087934/0/en/Sunesis-Pharmaceuticals-Announces-1-for-10-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split2020-09-02T16:48:24Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective as of 5:00 p.m. Eastern Time today. The reverse stock split was effected by Sunesis in accordance with the authorization, and within the split ratio range, adopted by Sunesis stockholders at the 2020 Annual Meeting of Stockholders held on June 16, 2020.]]>https://www.globenewswire.com/news-release/2020/08/11/2076704/0/en/Sunesis-Pharmaceuticals-Reports-Second-Quarter-2020-Financial-Results-and-Recent-Highlights.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights2020-08-11T20:05:00Z<![CDATA[Sunesis to Host Conference Call Today at 4:30 PM Eastern Time Sunesis to Host Conference Call Today at 4:30 PM Eastern Time]]>https://www.globenewswire.com/news-release/2020/08/04/2072290/0/en/Sunesis-Pharmaceuticals-to-Host-Conference-Call-on-August-11th-to-Discuss-Second-Quarter-2020-Financial-Results-and-Recent-Highlights.html?f=22&fvtc=4&fvtv=12227Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights2020-08-04T11:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2020.]]>https://www.globenewswire.com/news-release/2020/07/29/2069514/0/en/Sunesis-Announces-Pricing-of-12-Million-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12227Sunesis Announces Pricing of $12 Million Offering of Common Stock2020-07-29T13:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its common stock. The public offering price of each share of common stock is $0.23.]]>https://www.globenewswire.com/news-release/2020/07/28/2069017/0/en/Sunesis-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=12227Sunesis Announces Proposed Public Offering of Common Stock2020-07-28T20:07:27Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock, in an underwritten public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering. Sunesis also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offering to fund ongoing development of PDK1 inhibitor SNS-510 and general corporate purposes.]]>